Login to Your Account

Market Report Q312

Capital Flows Freely into Biotech Driven by Market Performance

By Peter Winter

Monday, October 8, 2012

Despite the continuing turbulence in the global capital markets investors have had no qualms about backing the biotech sector – more in public biotechs than in private ones, however. The average increase in the stock values of the 231 public biotech companies tracked by the BioWorld Stock Report is up 38 percent year-to-date.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription